MetLife Investment Management’s ClearPoint Neuro CLPT Stock Holding History

MetLife Investment Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139K	Hold	15,260	–	–	﹤0.01%	2392
2025 Q4	$209K	Buy	15,260 +4,002	+36%	+$74.2K	﹤0.01%	2252
2025 Q3	$245K	Sell	11,258 -4,567	-29%	-$53.8K	﹤0.01%	2202
2025 Q2	$189K	Buy	+15,825	New	+$199K	﹤0.01%	2231
2024 Q2	–	Sell	-12,254	Closed	-$70.9K	–	2889
2024 Q1	$83.3K	Hold	12,254	–	–	﹤0.01%	2618
2023 Q4	$83.2K	Hold	12,254	–	–	﹤0.01%	2681
2023 Q3	$61.4K	Hold	12,254	–	–	﹤0.01%	2800
2023 Q2	$88.7K	Buy	+12,254	New	+$104K	﹤0.01%	2746
2021 Q4	–	Sell	-7,721	Closed	-$137K	–	2506
2021 Q3	$137K	Hold	7,721	–	–	﹤0.01%	2293
2021 Q2	$147K	Buy	+7,721	New	+$149K	﹤0.01%	2334

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

MetLife Investment Management's CLPT Position: Q1 2026 in Review

MetLife Investment Management held its ClearPoint Neuro (CLPT) position steady in Q1 2026 at 15,260 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

MetLife Investment Management first reported a position in CLPT in Q2 2021 and has held it in 10 quarters since. The position peaked at $245K in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

MetLife Investment Management held 15,260 shares of ClearPoint Neuro worth $139K as of Q1 2026.
MetLife Investment Management left its ClearPoint Neuro share count unchanged in Q1 2026.
ClearPoint Neuro made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2392 holding.
MetLife Investment Management first reported a position in ClearPoint Neuro in Q2 2021 and has held it in 10 quarters since.
MetLife Investment Management's ClearPoint Neuro position peaked at $245K in Q3 2025.
118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.